Pharmacodynamics anadroll has antianginal, anti-hypoxic action. Directly affecting cardiomyocytes and neurons in the brain, improves their metabolism and function. Cytoprotective effect is due to an increase in energy potential, activation of oxidative decarboxylation and rationalization of consumption of oxygen (increased aerobic glycolysis and fatty acid oxidation blockade). It supports myocardial contractility, prevents a decrease in intracellular ATP and phosphocreatine. The conditions of acidosis normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, normalizes intracellular concentration of potassium ions. Reduces intracellular acidosis and phosphate, caused by myocardial ischemia and reperfusion. Prevents the damaging action of free radicals, preserves the integrity of cell membranes, prevent neutrophil activation in the area of ischemia increases the electrical potential, reduces androl 50 mg the yield of creatine kinase from the cells and the severity of ischemic myocardial damage. When angina reduces the frequency of attacks (reduced nitrate consumption), after 2 weeks of treatment increases exercise capacity, reduced blood pressure drops. Improves hearing and vestibular trial results in patients decreases dizziness and tinnitus. When vascular pathology eyes restores functional activity of the retina eyes.Pharmacokinetics After oral administration of anadroll is rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability – 90%. Time to reach maximum plasma concentration – 2 hours (maximum concentration after a single dose of 20 mg of anadroll about 55 ng / ml). Easily penetrates the blood-tissue barriers. The half-life (T ½ ) is 4.5-5 hours. Contact with blood plasma proteins – 16%. Report from the body by the kidneys (60% unchanged).
- Ischemic heart disease: prevention of angina attacks (in the complex therapy);
- Chorioretinal vascular disorders
- Vertigo of vascular origin;
- Cochle-vestibular disorders ischemic nature (tinnitus, hearing impairment).
- Hypersensitivity to any component of the drug;
- Renal impairment (creatinine clearance less than 15 mL / min);
- Severe hepatic dysfunction;
- The period of breast-feeding;
- Age 18 years (effectiveness and safety have been established).
DOSAGE AND ADMINISTRATION:
Inside, during a meal.
The recommended dosing regimen – 2-3 tablets (40-60 mg) per day, 2-3 hours. The course of treatment recommended by the doctor.
: Allergic reactions (itchy skin). Rarely from the gastrointestinal tract: gastralgia, nausea, vomiting; headache, feeling of palpitations.
Currently, cases of overdose have been reported.
Against the background of drug treatment in patients with coronary heart disease is a significant decrease in daily requirement of nitrates. Use of the drug has no effect on the ability to control the car and the performance of work requiring a high rate of mental and physical reactions.